---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-051045"
form_type: "8-K"
ticker: "CSTL"
cik: "0001447362"
company_name: "CASTLE BIOSCIENCES INC"
filed_at: "2026-07-30T20:06:54+00:00"
generated_at: "2026-07-30T20:08:32.220973+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Castle Biosciences Q2 revenue $103.5M (+20% YoY); raises FY2026 guidance to $365-375M

## Summary
- Q2 revenue $103.5M vs $86.2M YoY; net loss $2.1M (incl. $11.6M stock comp) vs net income $4.5M.
- Core test reports (DecisionDx-Melanoma, TissueCypher) up 32% YoY; TissueCypher reports surged 63% to 14,988.
- Raises FY2026 revenue guidance to $365-375M from $345-355M; expects positive Adjusted EBITDA in Q3, Q4, and full year.
- Adjusted EBITDA $12.4M vs $10.4M; cash $266.8M.
- AdvanceAD-Tx test received NYSDOH approval; first patient enrolled in DETECT-AD study.

## SEC filing metadata
- accession: 0001628280-26-051045
- form_type: 8-K
- ticker: CSTL
- cik: 0001447362
- company_name: CASTLE BIOSCIENCES INC
- filed_at: 2026-07-30T20:06:54+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447362/000162828026051045/0001628280-26-051045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447362/000162828026051045/cstl-20260730.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-051045
- JSON: https://secwatch.observer/filing/0001628280-26-051045.json
- Plain text: https://secwatch.observer/filing/0001628280-26-051045.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.